- Home
- SKM vs BPMC Comparison
SKM vs BPMC Comparison
Compare SKM & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKM
- BPMC
- Stock Information
- Founded
- SKM 1984
- BPMC 2008
- Country
- SKM South Korea
- BPMC United States
- Employees
- SKM N/A
- BPMC N/A
- Industry
- SKM Telecommunications Equipment
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- SKM Telecommunications
- BPMC Health Care
- Exchange
- SKM Nasdaq
- BPMC Nasdaq
- Market Cap
- SKM 8.2B
- BPMC 5.8B
- IPO Year
- SKM 1996
- BPMC 2015
- Fundamental
- Price
- SKM $21.49
- BPMC $90.11
- Analyst Decision
- SKM
- BPMC Buy
- Analyst Count
- SKM 0
- BPMC 20
- Target Price
- SKM N/A
- BPMC $125.00
- AVG Volume (30 Days)
- SKM 319.4K
- BPMC 1.0M
- Earning Date
- SKM 05-07-2025
- BPMC 05-01-2025
- Dividend Yield
- SKM 4.67%
- BPMC N/A
- EPS Growth
- SKM 21.68
- BPMC N/A
- EPS
- SKM 3.90
- BPMC N/A
- Revenue
- SKM $12,144,590,272.00
- BPMC $508,824,000.00
- Revenue This Year
- SKM $2.21
- BPMC $45.43
- Revenue Next Year
- SKM $1.83
- BPMC $32.80
- P/E Ratio
- SKM $9.85
- BPMC N/A
- Revenue Growth
- SKM 1.89
- BPMC 104.04
- 52 Week Low
- SKM $19.88
- BPMC $80.68
- 52 Week High
- SKM $24.58
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- SKM 45.59
- BPMC 43.48
- Support Level
- SKM $21.06
- BPMC $84.59
- Resistance Level
- SKM $21.94
- BPMC $90.00
- Average True Range (ATR)
- SKM 0.28
- BPMC 3.42
- MACD
- SKM -0.12
- BPMC 0.16
- Stochastic Oscillator
- SKM 21.61
- BPMC 51.11
About SKM SK Telecom Co. Ltd.
SK Telecom is South Korea's largest wireless telecom operator, with 32 million mobile customers. The firm also owns SK Broadband (formerly Hanaro Telecom), which has 7.2 million broadband customers and 9.6 million pay TV customers (6.8 million IPTV and 2.8 million Cable TV). While the firm also purchased stakes in businesses in security and semiconductor memory production as well as developing e-commerce and internet platform businesses, these were all spun off into the separate, SK Square business in November 2021. The company was formed after SK Group purchased KT's mobile business in 1994.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.